期刊论文Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials复制

DOI:复制

文献链接:复制

其他信息:

U Laufs, M Banach, HE Bays, AL Catapano, PB Duell…
Circulation, 2020
ahajournals.org
Introduction: Some patients cannot tolerate statins mainly because of statin-associated muscle symptoms (SAMS). Bempedoic acid (BA) is a prodrug activated in the liver and not in skeletal muscle. BA has been shown to significantly lower LDL-C by a mean of~ 18% in patients receiving background maximally tolerated statins and a mean of~ 25% in patients with statin intolerance. Objective: Determine efficacy and safety of BA in statin-intolerant patients receiving no background statin therapy across 4 phase 3 clinical trials. Methods …